Mizuho analyst Graig Suvannavejh views the recent pullback in shares of EyePoint (EYPT) as a buying opportunity. The company’s Q3 update was “fine,” with no major changes for lead asset Duravyu, the analyst tells investors in a research note. The firm says Duravyu remains on track in its two Phase 3 programs. Mizuho recommends buying the stock with an Outperform rating and $33 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint Pharmaceuticals Files $200M Stock Offering Prospectus
- EyePoint Pharmaceuticals: Strategic Advancements and Promising Developments Drive Buy Rating
- EyePoint Pharma Advances DURAVYU in Retinal Disease Trials
- EyePoint Pharma’s Earnings Call: Strategic Gains Amid Financial Hurdles
- EyePoint reports Q3 EPS (85c), consensus (77c)